Mahamaya Lifesciences Limited, a leading manufacturer and exporter of crop protection products and bioproducts, has announced the launch of its Initial Public Offering (IPO) to raise Rs. 70.44 crore through a Book Building issue.

The IPO comprises a fresh issue of 53, 29,200 equity shares aggregating up to ₹60.75 crore and an offer-for-sale of 5, 40,000 equity shares aggregating up to Rs. 6.16 crore. The issue will open for public subscription on November 11, 2025, and close on November 13, 2025. The basis of allotment is expected to be finalized on November 14, 2025. The company’s equity shares are proposed to be listed on the BSE SME platform, with a tentative listing date of November 18, 2025.

The price band for the IPO has been fixed at Rs. 108 to Rs. 114 per share, with a face value of Rs. 10 each. The minimum lot size for retail investors is 2,400 shares, requiring a minimum investment of Rs. 2,73,600, while the minimum investment for S-HNI investors is 3,600 shares, amounting to Rs. 4,10,400. The anchor investor portion was activated on November 10, 2025, successfully raising ₹19.97 crore.

The company plans to utilize the proceeds from the IPO to expand its existing formulation plant and establish a new technical manufacturing facility in Dahej, Gujarat. This strategic expansion aims to enhance its production capabilities and strengthen its position in the crop protection and bioproducts market.